Loic Vincent, Ph.D.

Chief Scientific Officer

Loïc Vincent, Ph.D., Chief Scientific Officer at Korro Bio, brings over 20 years of experience in drug discovery & translational research across academia, biotech and the pharmaceutical industry, with deep expertise in oncology and immunology-related disorders. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms, and cell therapies.

 

Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies. Previously, he was Head of the Oncology Drug Discovery Unit and Immunology Unit at Takeda. Before that, Dr. Vincent led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams at Sanofi, and earlier in his career, he headed Pharmacology and Oncology programs at Endotis Pharma. Dr. Vincent currently serves on the Scientific Advisory Boards of bit.bio and General Inception, and is a Director on the Board of Alaya.bio. Dr. Vincent obtained his Ph.D. in pharmacology from the University of Rouen, France, and completed his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University, New York.